Condition
MDS/MPN
Total Trials
5
Recruiting
3
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting3
Active Not Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT04061421Phase 1RecruitingPrimary
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT05582902Active Not Recruiting
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
NCT05153226Phase 3Active Not Recruiting
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT06211166Recruiting
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
NCT05817955Phase 2RecruitingPrimary
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Showing all 5 trials